The safety and efficacy of remiazolam besylate and cyclopol in painless bronchoscopy

Anesthesiology

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200067193

Enrollment

Unknown

Registered

2022-12-29

Start date

2023-01-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesiology

Interventions

Group R:remimazolam tosilate

Group C:Cyclopol

Eligibility

Sex/Gender

All

Age

35 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age 35 to 65; American Society of Anesthesiologists (ASA) Grade I-II, SpO2>90% when inhaling air into the room.

Exclusion criteria

Exclusion criteria: Known history of allergy to anesthetics (Remazolam benzenesulfonate, Cyclopol, Midazolam, Fentanyl); Chronic renal failure (glomerular filtration rate30 kg/m2); Allergies to the drugs used in the study; Operation time<15 minutes.

Design outcomes

Primary

Measure	Time frame
Operation completion success rate;	—

Secondary

Measure	Time frame
General information and hemodynamics of patients;Time indicator;Patient and bronchoscope doctor satisfaction scores;Patient's willingness to repeat bronchoscopy;Perioperative drug use;	—

Countries

China

Contacts

Public ContactSong Fei

Inner Mongolia Ordos Central Hospital

songfei1225@163.com15204778880

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026